LU83795A1 - Xanthates,leur preparation et leur utilisation - Google Patents

Xanthates,leur preparation et leur utilisation Download PDF

Info

Publication number: LU83795A1
Authority: LU; Luxembourg
Prior art keywords: xanthate; alkali metal; group; sodium; potassium
Prior art date: 1980-11-26

Application number

LU83795A

Other languages

English (en)

French (fr)

Inventor

Arthur Scherm

Klaus Hummel

Original Assignee

Merz & Co Gmbh & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-11-26

Filing date

1981-11-26

Publication date

1983-09-01

1981-11-26 Application filed by Merz & Co Gmbh & Co filed Critical Merz & Co Gmbh & Co

1983-09-01 Publication of LU83795A1 publication Critical patent/LU83795A1/fr

Links

239000012991 xanthate Substances 0.000 title claims description 38
238000002360 preparation method Methods 0.000 title claims description 9
-1 cyclododecyl Chemical group 0.000 claims description 29
ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 claims description 28
239000011734 sodium Substances 0.000 claims description 27
QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 claims description 25
229910052783 alkali metal Inorganic materials 0.000 claims description 23
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 22
229910052708 sodium Inorganic materials 0.000 claims description 22
150000001875 compounds Chemical class 0.000 claims description 19
150000001340 alkali metals Chemical group 0.000 claims description 17
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 16
229910052700 potassium Inorganic materials 0.000 claims description 16
239000011591 potassium Substances 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 15
125000000217 alkyl group Chemical group 0.000 claims description 14
238000000034 method Methods 0.000 claims description 12
125000005843 halogen group Chemical group 0.000 claims description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
238000006243 chemical reaction Methods 0.000 claims description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 6
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
229910052751 metal Inorganic materials 0.000 claims description 6
239000002184 metal Substances 0.000 claims description 6
230000001790 virustatic effect Effects 0.000 claims description 6
125000003545 alkoxy group Chemical group 0.000 claims description 5
125000004429 atom Chemical group 0.000 claims description 5
125000000753 cycloalkyl group Chemical group 0.000 claims description 5
KMJJWVCLFJXUQF-UHFFFAOYSA-M sodium;cyclohexyloxymethanedithioate Chemical compound [Na+].[S-]C(=S)OC1CCCCC1 KMJJWVCLFJXUQF-UHFFFAOYSA-M 0.000 claims description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
125000003282 alkyl amino group Chemical group 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
WIKDURKPSJEWGB-UHFFFAOYSA-N phenylmethoxymethanedithioic acid Chemical compound SC(=S)OCC1=CC=CC=C1 WIKDURKPSJEWGB-UHFFFAOYSA-N 0.000 claims description 3
125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims description 3
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 2
241000212342 Sium Species 0.000 claims description 2
239000003513 alkali Substances 0.000 claims description 2
239000002168 alkylating agent Substances 0.000 claims description 2
229940100198 alkylating agent Drugs 0.000 claims description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 2
125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims description 2
OPLBMJFYACKMRJ-UHFFFAOYSA-N o-cyclohexyl methylsulfanylmethanethioate Chemical compound CSC(=S)OC1CCCCC1 OPLBMJFYACKMRJ-UHFFFAOYSA-N 0.000 claims description 2
QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 claims 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
241000208202 Linaceae Species 0.000 claims 1
235000004431 Linum usitatissimum Nutrition 0.000 claims 1
DXHPZXWIPWDXHJ-UHFFFAOYSA-N carbon monosulfide Chemical compound [S+]#[C-] DXHPZXWIPWDXHJ-UHFFFAOYSA-N 0.000 claims 1
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 1
125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
JZGDVCTYNFVQEC-UHFFFAOYSA-M potassium;adamantane-1-carboxylate Chemical compound [K+].C1C(C2)CC3CC2CC1(C(=O)[O-])C3 JZGDVCTYNFVQEC-UHFFFAOYSA-M 0.000 claims 1
QDIGBJJRWUZARS-UHFFFAOYSA-M potassium;decanoate Chemical compound [K+].CCCCCCCCCC([O-])=O QDIGBJJRWUZARS-UHFFFAOYSA-M 0.000 claims 1
UONHJSWTEBJXNB-UHFFFAOYSA-M potassium;heptoxymethanedithioate Chemical compound [K+].CCCCCCCOC([S-])=S UONHJSWTEBJXNB-UHFFFAOYSA-M 0.000 claims 1
GBBPFRKNGUDLLB-UHFFFAOYSA-M sodium;cyclododecanecarboxylate Chemical compound [Na+].[O-]C(=O)C1CCCCCCCCCCC1 GBBPFRKNGUDLLB-UHFFFAOYSA-M 0.000 claims 1
LFQULJPVXNYWAG-UHFFFAOYSA-N sodium;phenylmethanolate Chemical compound [Na]OCC1=CC=CC=C1 LFQULJPVXNYWAG-UHFFFAOYSA-N 0.000 claims 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
239000000243 solution Substances 0.000 description 16
239000000126 substance Substances 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
241000700605 Viruses Species 0.000 description 8
230000000840 anti-viral effect Effects 0.000 description 8
238000001816 cooling Methods 0.000 description 8
239000007788 liquid Substances 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
238000004458 analytical method Methods 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
238000002844 melting Methods 0.000 description 7
230000008018 melting Effects 0.000 description 7
238000010992 reflux Methods 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
238000000354 decomposition reaction Methods 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
210000004883 areola Anatomy 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
206010022000 influenza Diseases 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
229910052573 porcelain Inorganic materials 0.000 description 3
239000000047 product Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Chemical group CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
239000000463 material Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000000967 suction filtration Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
241000712461 unidentified influenza virus Species 0.000 description 2
125000006755 (C2-C20) alkyl group Chemical group 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
240000008886 Ceratonia siliqua Species 0.000 description 1
235000013912 Ceratonia siliqua Nutrition 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
244000298479 Cichorium intybus Species 0.000 description 1
235000007542 Cichorium intybus Nutrition 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
241000353621 Eilat virus Species 0.000 description 1
235000014066 European mistletoe Nutrition 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
244000152640 Rhipsalis cassutha Species 0.000 description 1
235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
VLLNJDMHDJRNFK-UHFFFAOYSA-N adamantan-1-ol Chemical compound C1C(C2)CC3CC2CC1(O)C3 VLLNJDMHDJRNFK-UHFFFAOYSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
210000001691 amnion Anatomy 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000005188 flotation Methods 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000004009 herbicide Substances 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000001055 magnesium Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
238000002962 plaque-reduction assay Methods 0.000 description 1
ROKMMAWTMJKDKE-UHFFFAOYSA-M potassium;decoxymethanedithioate Chemical compound [K+].CCCCCCCCCCOC([S-])=S ROKMMAWTMJKDKE-UHFFFAOYSA-M 0.000 description 1
ZTHBGWDIOJXYNC-UHFFFAOYSA-M potassium;hexoxymethanedithioate Chemical class [K+].CCCCCCOC([S-])=S ZTHBGWDIOJXYNC-UHFFFAOYSA-M 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940098465 tincture Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
125000006168 tricyclic group Chemical group 0.000 description 1
125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000004073 vulcanization Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C329/00—Thiocarbonic acids; Halides, esters or anhydrides thereof
- C07C329/02—Monothiocarbonic acids; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C329/00—Thiocarbonic acids; Halides, esters or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Emergency Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

LU83795A 1980-11-26 1981-11-26 Xanthates,leur preparation et leur utilisation LU83795A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE3044525		1980-11-26
DE3044525		1980-11-26

Publications (1)

Publication Number	Publication Date
LU83795A1 true LU83795A1 (fr)	1983-09-01

Family

ID=6117628

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU83795A LU83795A1 (fr)	1980-11-26	1981-11-26	Xanthates,leur preparation et leur utilisation

Country Status (24)

Country	Link
US (2)	US4602037A (de)
JP (2)	JPS5943944B2 (de)
KR (1)	KR870001238B1 (de)
AR (1)	AR230264A1 (de)
AT (1)	AT376202B (de)
AU (1)	AU549653B2 (de)
BE (1)	BE891245A (de)
CA (1)	CA1175047A (de)
CH (1)	CH651546A5 (de)
DE (1)	DE3146772C2 (de)
DK (1)	DK170068B1 (de)
ES (1)	ES8400398A1 (de)
FR (1)	FR2494689B1 (de)
GB (1)	GB2091244B (de)
GR (1)	GR76308B (de)
HU (1)	HU187476B (de)
IE (1)	IE51944B1 (de)
IT (1)	IT1195297B (de)
LU (1)	LU83795A1 (de)
NL (1)	NL8105326A (de)
PL (1)	PL129383B1 (de)
SE (1)	SE450251B (de)
SG (1)	SG29285G (de)
YU (1)	YU42120B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR230264A1 (es) *	1980-11-26	1984-03-01	Merz & Co Gmbh & Co	Procedimiento para la obtencion de compuestos de xantato
DE3625948A1 (de) *	1985-08-02	1987-02-19	Merz & Co Gmbh & Co	Antivirale und antitumor-zusammensetzung, verfahren zu deren herstellung und deren verwendung
IT1213453B (it) *	1985-08-02	1989-12-20	Merz & Co Gmbh & Co	Composizione farmaceutica.
AT388499B (de) *	1985-08-02	1989-06-26	Merz & Co Gmbh & Co	Verfahren zur herstellung einer antiviralen und antitumor-zusammensetzung, und deren verwendung
US5055296A (en) *	1988-08-04	1991-10-08	Wagle Sudhakar S	Method of treating chronic fatigue syndrome
US5334395A (en) *	1988-08-04	1994-08-02	Kremers-Urban Company	Method of treating an epstein-barr viral infection
US5316775A (en) *	1988-08-04	1994-05-31	Kremers-Urban Company	Method of treating hepatitis B infection
US5284664A (en) *	1988-08-04	1994-02-08	Kremers-Urban Company	Method of treating the symptoms of Alzheimer's disease
EP0450492A1 (de) *	1990-04-06	1991-10-09	Tosoh Corporation	Alkylxanthogenate, ihre Herstellung, Fotopolymerisationsinitiator, ihn verwendende Fotopolymerisation
AU4159596A (en) *	1994-11-14	1996-06-06	Ct-Holding Sa	Antiviral and antitumor pharmaceutical compositions
DE10117728A1 (de) *	2001-04-09	2002-10-17	Biosphings Ag	Pharmazeutische Formulierungen für Xanthogenate
DE10156617A1 (de) *	2001-11-17	2003-05-28	Biosphings Ag	Herstellung reiner Stereoisomere von Tricyclo[5.2.1.0··2··.··6··]-dec-9-yl-xanthogenat und Arzneimittel daraus
EP1391221A1 (de) *	2002-08-23	2004-02-25	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Pharmazeutische Zubereitung enthaltend Palladiumkomplexverbindungen und deren Verwendung zur Behandlung von Krebs und Autoimmunerkrankungen
DE10343365A1 (de) *	2003-09-17	2005-04-14	Biosphings Ag	Pharmazeutische Formulierungen von Xanthogenaten und Hemmstoffen der viralen Nukleinsäurereplikation
DE102005031265A1 (de) *	2005-07-05	2007-01-18	Sms Demag Ag	Spreizbarer Haspeldorn
DE102006014390A1 (de)	2006-03-29	2007-10-04	Biosphings Ag	Assoziate von Xanthogenaten mit Cyclodextrinen und ihre Verwendung
BRPI0812821A2 (pt) *	2007-07-03	2014-12-09	Lumavita Ag	Composto, composição farmacêutica, e, métodos para inibir uma infecção viral e a atividade de fosfolipase c, para preparar o composto, e para tratar, prevenir ou melhorar uma doença
ES2727702T3 (es) *	2008-07-15	2019-10-18	Callery Llc	Procedimiento para purificar sulfuros de dialquilo
US20100221809A1 (en) *	2008-12-23	2010-09-02	The Regents Of The University Of California	Compositions and Methods for the Isolation of Biologically Active Proteins
CN114478339B (zh) *	2022-02-14	2023-12-08	中南大学	一种黄原酸盐类捕收剂的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1854525A (en) *	1929-11-11	1932-04-19	Shell Dev	Tertiary xanthates
US1886587A (en) *	1930-01-09	1932-11-08	Hercules Powder Co Ltd	Method of preparing xanthates of terpene alcohols
US2037717A (en) *	1932-11-09	1936-04-21	Du Pont	Xanthates and method of making same
US2037718A (en) *	1932-11-09	1936-04-21	Du Pont	Xanthates and method of making same
FR790353A (fr) *	1934-05-22	1935-11-20	Bataafsche Petroleum	Préparation de xanthates
US2161584A (en) *	1936-08-01	1939-06-06	Socony Vacuum Oil Co Inc	Petroleum lubricant composition
US2811432A (en) *	1953-07-17	1957-10-29	Monsanto Chemicals	Herbicidal composition
US3864469A (en) *	1967-12-16	1975-02-04	Hoechst Ag	Xanthines in pharmaceutical preparations and for stabilization of vitamins
US3864417A (en) *	1970-01-16	1975-02-04	Chevron Res	Saturated hydrocarbon disproportionation at low temperatures
ZA715615B (en) *	1970-10-05	1972-04-26	American Cyanamid Co	Manufacture of alkali metal xanthates
US3965137A (en) *	1974-05-02	1976-06-22	Stauffer Chemical Company	Thiocyano xanthates
AR230264A1 (es) *	1980-11-26	1984-03-01	Merz & Co Gmbh & Co	Procedimiento para la obtencion de compuestos de xantato

1981
- 1981-11-24 AR AR287572A patent/AR230264A1/es active
- 1981-11-24 DK DK522081A patent/DK170068B1/da not_active IP Right Cessation
- 1981-11-24 KR KR1019810004542A patent/KR870001238B1/ko not_active Expired
- 1981-11-25 DE DE3146772A patent/DE3146772C2/de not_active Expired - Fee Related
- 1981-11-25 PL PL1981233966A patent/PL129383B1/pl unknown
- 1981-11-25 IE IE2768/81A patent/IE51944B1/en not_active IP Right Cessation
- 1981-11-25 NL NL8105326A patent/NL8105326A/nl not_active Application Discontinuation
- 1981-11-25 ES ES507430A patent/ES8400398A1/es not_active Expired
- 1981-11-25 SE SE8107022A patent/SE450251B/sv not_active IP Right Cessation
- 1981-11-25 GB GB8135536A patent/GB2091244B/en not_active Expired
- 1981-11-25 HU HU813521A patent/HU187476B/hu not_active IP Right Cessation
- 1981-11-25 FR FR8122055A patent/FR2494689B1/fr not_active Expired
- 1981-11-25 CA CA000390861A patent/CA1175047A/en not_active Expired
- 1981-11-25 BE BE0/206650A patent/BE891245A/fr not_active IP Right Cessation
- 1981-11-26 GR GR66624A patent/GR76308B/el unknown
- 1981-11-26 AT AT0510181A patent/AT376202B/de not_active IP Right Cessation
- 1981-11-26 AU AU77928/81A patent/AU549653B2/en not_active Ceased
- 1981-11-26 CH CH7576/81A patent/CH651546A5/de not_active IP Right Cessation
- 1981-11-26 IT IT25291/81A patent/IT1195297B/it active
- 1981-11-26 JP JP56188502A patent/JPS5943944B2/ja not_active Expired
- 1981-11-26 LU LU83795A patent/LU83795A1/fr unknown
- 1981-11-26 YU YU2782/81A patent/YU42120B/xx unknown
1983
- 1983-05-13 US US06/494,393 patent/US4602037A/en not_active Expired - Fee Related
- 1983-05-24 JP JP58091411A patent/JPS591416A/ja active Granted
1985
- 1985-04-22 SG SG292/85A patent/SG29285G/en unknown
1989
- 1989-12-29 US US07/458,889 patent/US4981869A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
GB2091244A (en)	1982-07-28
SE8107022L (sv)	1982-05-27
IT1195297B (it)	1988-10-12
YU42120B (en)	1988-04-30
JPS57118557A (en)	1982-07-23
ES507430A0 (es)	1983-11-01
YU278281A (en)	1984-02-29
SG29285G (en)	1985-11-15
GB2091244B (en)	1985-02-06
JPS5943944B2 (ja)	1984-10-25
US4602037A (en)	1986-07-22
JPS6328410B2 (de)	1988-06-08
FR2494689B1 (fr)	1986-07-25
AR230264A1 (es)	1984-03-01
CA1175047A (en)	1984-09-25
DE3146772A1 (de)	1982-09-02
CH651546A5 (de)	1985-09-30
ES8400398A1 (es)	1983-11-01
PL129383B1 (en)	1984-05-31
DK522081A (da)	1982-05-27
ATA510181A (de)	1984-03-15
IE51944B1 (en)	1987-04-29
FR2494689A1 (fr)	1982-05-28
AU549653B2 (en)	1986-02-06
IT8125291A0 (it)	1981-11-26
DK170068B1 (da)	1995-05-15
GR76308B (de)	1984-08-04
US4981869A (en)	1991-01-01
SE450251B (sv)	1987-06-15
IE812768L (en)	1982-05-26
JPS591416A (ja)	1984-01-06
DE3146772C2 (de)	1994-09-22
HU187476B (en)	1986-01-28
BE891245A (fr)	1982-05-25
PL233966A1 (de)	1982-07-05
AU7792881A (en)	1982-07-08
AT376202B (de)	1984-10-25
KR830007648A (ko)	1983-11-04
KR870001238B1 (ko)	1987-06-26
NL8105326A (nl)	1982-06-16

Publication	Publication Date	Title
LU83795A1 (fr)	1983-09-01	Xanthates,leur preparation et leur utilisation
FR2532844A1 (fr)	1984-03-16	Composition pharmaceutique contenant un compose polyprenylique
EP0015038A1 (de)	1980-09-03	Ein Diphenylhydantoin-Derivat enthaltende pharmazeutische Zusammensetzung, verwendete Derivate und ihre Herstellung
EP0087378B1 (de)	1988-10-26	Oximäther von Alkylaminoalkoholen als Heilmittelverbindungen und Verfahren zu ihrer Herstellung
CA1216859A (fr)	1987-01-20	Procede de preparation de nouveaux derives de l'acide 4-phenyl 4-oxo buten-2-oique
FR2481271A1 (fr)	1981-10-30	Derives de la nonaprenylamine, leurs sels acides d'addition et leur utilisation dans des compositions pharmaceutiques
CH661661A5 (fr)	1987-08-14	Agent antineoplasique.
WO1990006931A1 (fr)	1990-06-28	Composes organometalliques, leurs modes de preparation et compositions pharmaceutiques les contenant
EP1268470B1 (de)	2008-02-27	Duale moleküle enthaltend ein peroxydderivat deren synthese und deren verwendung als heilmittel
FR2492821A1 (fr)	1982-04-30	Derives de la pyrimidine, leur procede de preparation et les compositions pharmaceutiques les contenant
EP0002635A1 (de)	1979-06-27	Verfahren zur Herstellung von Thieno (2,3-c)-bzw. (3,2-c) pyridinderivaten, so erhaltene Thieno (2,3-c) pyridinderivate und ihre therapeutische Anwendung
CA1174978A (en)	1984-09-25	Xanthates
KR20020043249A (ko)	2002-06-08	염증 치료용 6-메톡시-2-나프틸아세트산 전구약물
EP0022017A1 (de)	1981-01-07	Derivate von 2-Benzoyl-4-nitro-aniliden, deren Herstellung und deren Verwendung als Heilmittel
EP0008269B1 (de)	1984-02-01	Arzneimittel, die als aktive Substanz Verbindungen des Benzensulfon-Typs enthalten, Verbindungen dieses Typs und Verfahren zu ihrer Herstellung
EP0482993A1 (de)	1992-04-29	N,O-Spirocyclische Cyclotriphosphazen-Derivate, ihre Herstellung und ihre therapeutische Verwendung
EP0002638B1 (de)	1982-01-20	Additionssalze von substituierten Aralkylaminen und diese enthaltende pharmazeutische Zusammensetzung
FR2517672A1 (fr)	1983-06-10	Thioalcanoyl-carnitines, procede pour leur preparation et composition pharmaceutique les contenant
CH642961A5 (fr)	1984-05-15	Beta-lactones derivees de l'acide 2-hydroxy cyclopentane carboxylique, leurs procedes de preparation et les compositions pharmaceutiques les renfermant.
FR1450548A (fr)	1966-08-26	Nouveaux dérivés polyhydroxylés des benzimidazoles
EP0210886B1 (de)	1988-08-24	Tertiäre halogenierte Biphenylalkohole die nützlich in der Therapeutik bei der Behandlung von Atheriosklerose sind
EP0039294B1 (de)	1984-02-29	Bis-(substituierte Phenoxyacetate) von N-Alkyl-dialkanolaminen, Verfahren zu ihrer Bereitung, und diese enthaltende pharmazeutische Zusammensetzungen
MC1069A1 (fr)	1976-05-21	Derives de l'acide 5-acetylsalicylique et medicament contenant ces substances
FR2479812A1 (fr)	1981-10-09	Cycloalcoyl propanol amines utiles comme medicaments et procede pour leur preparation
FR2508907A1 (fr)	1983-01-07	Esters d'hydroxybenzenes substitues de 2-thenoylmercaptopropionylglycine utiles notamment comme mucolytiques, procede pour leur preparation et compositions pharmaceutiques les contenant